Abion Inc.
ABION Inc. operates as a pharmaceutical biotech Company in South Korea and internationally. The company develops anticancer therapeutic drugs, such as ABN401, a tyrosine kinase inhibitor that is in Phase II clinical trials for treating non-small cell lung cancer, as well as in Phase I clinical trial for breast cancer; ABN501, a human monoclonal antibody that targets claudin 3 for treating solid c… Read more
Abion Inc. (203400) - Total Assets
Latest total assets as of June 2025: ₩43.41 Billion KRW
Based on the latest financial reports, Abion Inc. (203400) holds total assets worth ₩43.41 Billion KRW as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abion Inc. - Total Assets Trend (2016–2024)
This chart illustrates how Abion Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abion Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Abion Inc.'s total assets of ₩43.41 Billion consist of 8.3% current assets and 91.7% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩3.17 Billion | 5.0% |
| Accounts Receivable | ₩18.70 Million | 0.0% |
| Inventory | ₩0.00 | 0.0% |
| Property, Plant & Equipment | ₩13.54 Billion | 21.2% |
| Intangible Assets | ₩3.74 Million | 0.0% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Abion Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abion Inc.'s current assets represent 8.3% of total assets in 2024, a decrease from 54.0% in 2016.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2024, down from 42.6% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 21.2% of total assets.
Abion Inc. Competitors by Total Assets
Key competitors of Abion Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Abion Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Abion Inc. generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Abion Inc. is currently not profitable relative to its asset base.
Abion Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.33 | 0.13 |
| Quick Ratio | 0.09 | 0.33 | 0.13 |
| Cash Ratio | 0.00 | 0.00 | 0.11 |
| Working Capital | ₩-26.36 Billion | ₩ -12.87 Billion | ₩ -39.80 Billion |
Abion Inc. - Advanced Valuation Insights
This section examines the relationship between Abion Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 19.12 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 42.8% |
| Total Assets | ₩63.78 Billion |
| Market Capitalization | $75.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Abion Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Abion Inc.'s assets grew by 42.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abion Inc. (2016–2024)
The table below shows the annual total assets of Abion Inc. from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩63.78 Billion | +42.77% |
| 2023-12-31 | ₩44.67 Billion | +85.03% |
| 2022-12-31 | ₩24.14 Billion | -45.89% |
| 2021-12-31 | ₩44.62 Billion | +233.75% |
| 2020-12-31 | ₩13.37 Billion | +40.90% |
| 2019-12-31 | ₩9.49 Billion | +20.12% |
| 2018-12-31 | ₩7.90 Billion | -5.43% |
| 2017-12-31 | ₩8.35 Billion | -35.51% |
| 2016-12-31 | ₩12.95 Billion | -- |